|1.||Szefler, Stanley J: 8 articles (02/2014 - 04/2007)|
|2.||Bacharier, Leonard B: 6 articles (02/2014 - 12/2008)|
|3.||Lemanske, Robert F: 6 articles (02/2014 - 04/2007)|
|4.||Bäck, Magnus: 6 articles (01/2013 - 01/2006)|
|5.||Sorkness, Christine A: 6 articles (09/2010 - 04/2007)|
|6.||Zeiger, Robert S: 5 articles (02/2014 - 12/2008)|
|7.||Chinchilli, Vernon M: 5 articles (09/2010 - 04/2007)|
|8.||Reiss, T F: 5 articles (09/2001 - 04/2000)|
|9.||Strunk, Robert C: 4 articles (09/2010 - 12/2008)|
|10.||Tozzi, Carol A: 4 articles (06/2009 - 03/2004)|
|1.||Asthma (Bronchial Asthma)
10/01/2001 - "Treatment with leukotriene-receptor antogonists (LTA) showed primarily good results in therapy of ASS-associated asthma. "
11/14/1998 - "[Leukotriene receptor antagonist effective in chronic asthma]."
09/01/2012 - "We prefer to double the dose of ICS instead of adding a long-acting β-agonist in step 3; ICS instead of leukotriene receptor antagonist are the first choice in preschool wheeze, and extra fine particle ICS formulations are not first-line treatment in children with asthma. "
02/01/2014 - "A post hoc analysis from the Best Add-On Giving Effective Response (BADGER) study tested the association between baseline biological, asthma control, pulmonary function, and demographic markers and responsiveness to step-up to a higher dose of inhaled corticosteroid (ICS step-up therapy) or addition of leukotriene receptor antagonist (LTRA step-up therapy) or long-acting β₂-agonist (LABA step-up therapy). "
03/01/2013 - "Few studies have examined the efficacy or safety of a transdermal β(2) agonist as add-on medication to long-term leukotriene receptor antagonist (LTRA) therapy in pediatric asthma patients. "
09/01/2010 - "Our data provided both objective and subjective evidence that leukotriene receptor antagonist-antihistamine combination therapy is more effective than antihistamine alone in the control of allergic rhinitis symptoms."
11/01/2009 - "Leukotriene receptor antagonist in the treatment of childhood allergic rhinitis--a randomized placebo-controlled study."
04/01/2005 - "Leukotriene receptor antagonist is a new drug to treat allergic rhinitis."
04/01/2012 - "Specific trials, sized according to the results of this pilot exploratory study, could add relevant evidences concerning the leukotrienes receptors antagonist treatment of specific rhinitis and asthma phenotypes."
01/01/2010 - "A comparison of intranasal corticosteroid, leukotriene receptor antagonist, and topical antihistamine in reducing symptoms of perennial allergic rhinitis as assessed through the Rhinitis Severity Score."
12/01/2014 - "The efficacy of the combination of leukotriene receptor antagonist (LRA) and H1 antihistamine was similar to the synergistic regimen of H1 and H2 antihistamine for treatment of chronic idiopathic urticaria (CIU). "
12/01/2014 - "Efficacy of leukotriene receptor antagonist with anti-H1 receptor antagonist plus anti-H2 receptor antagonist for treatment of refractory chronic idiopathic urticaria."
01/01/2009 - "Efficacy of leukotriene receptor antagonist with an anti-H1 receptor antagonist for treatment of chronic idiopathic urticaria."
10/01/2001 - "Efficacy of leukotriene receptor antagonist in chronic urticaria. "
11/01/2015 - "Treatment of solar urticaria using antihistamine and leukotriene receptor antagonist combinations tailored to disease severity."
10/01/2005 - "Adding a leukotriene receptor antagonist can provide a complementary effect of controlling inflammation, with a significant improvement in quality of life."
12/01/2013 - "Inflammation changes the expression of leukotriene receptors in porcine uteri."
01/01/2007 - "Leukotriene receptors: crucial components in vascular inflammation."
01/01/2011 - "The cysteinyl leukotrienes receptors (CysLTRs) are implicated in many different pathological conditions, such as inflammation and cancer. "
03/01/2008 - "Therefore, maintenance therapy with inhaled corticosteroid or leukotriene receptor antagonist can provide further improvements in asthma symptoms, pulmonary function, and airway inflammation, and discontinuation of the therapy causes worsening of asthma, indicating that stopping or interrupting anti-inflammatory therapy may not be advisable in patients with symptomatic mild intermittent asthma."
08/01/2005 - "In the present study, we investigated whether the leukotriene receptor blocker montelukast is protective against burn-induced remote organ injury. "
06/01/2005 - "In the present study, we investigated whether the leukotriene receptor blocker montelukast is protective against burn-induced injury of the gut. "
08/01/2005 - "Leukotriene receptor blocker montelukast protects against burn-induced oxidative injury of the skin and remote organs."
06/01/2005 - "Burn-induced oxidative injury of the gut is ameliorated by the leukotriene receptor blocker montelukast."
|8.||Arachidonate 5-Lipoxygenase (5 Lipoxygenase)
|9.||Aspirin (Acetylsalicylic Acid)
|2.||Nebulizers and Vaporizers (Inhaler)
|3.||Respiratory Therapy (Therapy, Respiratory)
|5.||Metered Dose Inhalers (Metered Dose Inhaler)